Kaskela Law LLC announces that it is investigating Sensei Biotherapeutics, Inc. (“Sensei”) (NASDAQ: SNSE) on behalf of the company’s investors.

Since August 2022, shares of Sensei’s common stock have declined over 37% in value, from a trading price of approximately $2.20 per share to a current value of $1.38 per share.

The investigation seeks to determine whether the decline in Sensei’s stock price may be attributable to the issuance of false and/or misleading statements and/or the failure to disclose material information to investors, in violation of the securities laws.

Sensei stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by completing the form on this page, for additional information about this investigation and their legal rights and options.